| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1749-6632.1965.TB20235.X |
| P2093 | author name string | George A. Schumacher | |
| Leonard T. Kurland | |||
| Benedict Nagler | |||
| Fletcher McDowell | |||
| Gilbert Beebe | |||
| John F. Kurtzke | |||
| Robert F. Kibler | |||
| Thomas L. Willmon | |||
| Wallace W. Tourtellotte | |||
| William A. Sibley | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 552-568 | |
| P577 | publication date | 2006-12-16 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS | |
| P478 | volume | 122 |
| Q57913671 | 2010 McDonald criteria for diagnosing pediatric multiple sclerosis |
| Q43266202 | 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis |
| Q40507937 | A Mechanistic, Stochastic Model Helps Understand Multiple Sclerosis Course and Pathogenesis |
| Q42924687 | A case of chronic progressive myelopathy |
| Q69573426 | A chromosome study in multiple sclerosis |
| Q70782584 | A goodness‐of‐fit test for the polygenic threshold model: Application to multiple sclerosis |
| Q48650575 | A longitudinal real-life comparison study of natalizumab and fingolimod. |
| Q67899471 | A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-γ in multiple sclerosis CSF and serum |
| Q40802954 | A novel haplotype of the endogenous retrovirus, HRES-1, in patients with multiple sclerosis and healthy individuals |
| Q66951794 | A numerical scoring system for the classification of multiple sclerosis |
| Q39433838 | A possible association between house pets and multiple sclerosis |
| Q68101004 | A prevalence study of multiple sclerosis in L'Aquila, central Italy |
| Q73094188 | A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials |
| Q69907548 | A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group |
| Q36206179 | A review of stress-relapse interactions in multiple sclerosis: important features and stress-mediating and -moderating variables |
| Q38881956 | A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study |
| Q57601914 | A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis |
| Q72662896 | A «Spontaneous» Cold-Reactive IgM Antibody with AntiHLA- B8 Specificity in a Patient with Multiple Sclerosis |
| Q72620004 | Abnormalities in native and dissociated α2-macroglobulin isolated from multiple sclerosis serum |
| Q53178623 | Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients |
| Q37808715 | Accuracy of diagnostic tests in multiple sclerosis - a systematic review |
| Q24241139 | Acupuncture for multiple sclerosis |
| Q24246259 | Amantadine for fatigue in multiple sclerosis |
| Q24248702 | Amantadine for fatigue in multiple sclerosis |
| Q52039836 | An expert system for the evaluation of EDSS in multiple sclerosis |
| Q38600051 | An update on cladribine for relapsing-remitting multiple sclerosis |
| Q39027028 | An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis |
| Q55490629 | Analysis of leukocyte adherence to measles-infected cells in multiple sclerosis |
| Q34214102 | Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod |
| Q24187386 | Anticholinergics for urinary symptoms in multiple sclerosis |
| Q24241666 | Anticholinergics for urinary symptoms in multiple sclerosis |
| Q28295788 | Application of the 2010 revised criteria for the diagnosis of multiple sclerosis to patients with clinically isolated syndromes |
| Q56600861 | Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis |
| Q34513928 | Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. |
| Q34491595 | Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. |
| Q35078327 | Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future |
| Q44820307 | CD21+ (B2 antigen+) cell decrement and CD4+ CD29+ (helper-inducer) cell increment suggest an activation of cell immune reactivity in multiple sclerosis |
| Q38358092 | CSF Electrophoresis: An Adaptation Using Cellulose Acetate for the Identification of Oligoclonal Banding |
| Q67287407 | CSF electrophoresis in one thousand patients |
| Q71084536 | CT and EEG investigations in 100 patients with multiple sclerosis (MS) |
| Q56905368 | CTLA4 in multiple sclerosis. Lack of genetic association in a European Caucasian population but evidence of interaction with HLA-DR2 among Shanghai Chinese |
| Q40148514 | Canadian Expert Panel Recommendations for MRI Use in MS Diagnosis and Monitoring |
| Q24197748 | Carnitine for fatigue in multiple sclerosis |
| Q24240036 | Carnitine for fatigue in multiple sclerosis |
| Q24242583 | Carnitine for fatigue in multiple sclerosis |
| Q41622180 | Case finding for epidemiological surveys of multiple sclerosis in United States communities |
| Q48881808 | Cell-mediated cytotoxicity by peripheral blood lymphocytes against basic protein of myelin, encephalitogenic peptide, cerebrosides and gangliosides in multiple sclerosis |
| Q48952335 | Cell-mediated immunity in multiple sclerosis as determined by sensitivity of different lymphocyte populations to various brain tissue antigens |
| Q53853284 | Cells producing antibodies specific for myelin basic protein region 70-89 are predominant in cerebrospinal fluid from patients with multiple sclerosis |
| Q39509331 | Cellular and Humoral Responses to Myelin Basic Protein in Multiple Sclerosis: A Dichotomy |
| Q51008789 | Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: Yes |
| Q72428715 | Cerebrospinal-fluid lymphocyte populations and immune complexes in active multiple sclerosis |
| Q39320035 | Characteristic gamma globulin subfraction of native CSF in mulltiple sclerosis |
| Q23918973 | Characteristics of disease and some exposure considerations |
| Q54491075 | Chronic intractable pain: An atypical presentation of multiple sclerosis |
| Q39580726 | Chronic progressive myelopathy: Investigation with CSF electrophoresis, evoked potentials, and CT scan |
| Q72770973 | Circulating immune complexes and complement in the course of multiple sclerosis |
| Q48772918 | Clinical Spectrum of Multiple Sclerosis |
| Q85046270 | Clinical and etiological aspects of uveitis: a retrospective study of 121 patients referred to a tertiary centre of ophthalmology |
| Q39906275 | Clinical features of multiple sclerosis in north-east Scotland |
| Q79186235 | Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis |
| Q53824227 | Clinical predictors of disease progression in multiple sclerosis patients with relapsing onset in a nation-wide cohort. |
| Q55357380 | Cognition During and After Multiple Sclerosis Relapse as Assessed With the Brief International Cognitive Assessment for Multiple Sclerosis. |
| Q41721827 | Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis |
| Q40946229 | Comparative geography of rheumatic fever and rheumatic heart disease, multiple sclerosis, and rheumatoid arthritis |
| Q72712370 | Comparison of a non-competitive two-site RIA and an inhibition RIA for the detection of myelin basic protein in cerebrospinal fluid |
| Q48795479 | Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial |
| Q40203363 | Computerized tomography in patients with multiple sclerosis |
| Q40724148 | Contribution of different relapse phenotypes to disability in multiple sclerosis. |
| Q22252578 | Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy |
| Q31119031 | Data quality evaluation for observational multiple sclerosis registries |
| Q72440682 | Deficit of suppressor T cells in active multiple sclerosis |
| Q52149517 | Defining reliable disability outcomes in multiple sclerosis |
| Q72644727 | Degradation of basic protein and Wolfgram protein in central nervous system myelin by soluble enzymes of human peripheral polymorphonuclear leucocytes |
| Q71029627 | Delayed auditory tone perception in multiple sclerosis |
| Q39564143 | Delayed hypersensitivity to human encephalitogenic protein as assayed by agarose leucocyte migration in multiple sclerosis patients |
| Q45882424 | Determination of measles virus-specific nucleocapsid antibodies by means of counterimmunoelectrophoresis |
| Q33645212 | Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy |
| Q47220919 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria |
| Q29030707 | Diagnostic Criteria, Classification and Treatment Goals in Multiple Sclerosis: The Chronicles of Time and Space |
| Q30648949 | Diagnostic criteria for multiple sclerosis |
| Q24605493 | Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria |
| Q22252293 | Diagnostic criteria for multiple sclerosis: an historical review |
| Q39604139 | Diagnostic value of determinations of lysosomal hydrolases in CSF of patients with neurological diseases |
| Q30495739 | Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities and specificities for reclassification according to the Poser committee criteria |
| Q24202428 | Dietary interventions for multiple sclerosis |
| Q31113892 | Differential diagnosis of multiple sclerosis |
| Q82967273 | Disability and survival of multiple sclerosis in Saskatoon, Saskatchewan |
| Q35094706 | Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies |
| Q30988818 | Diversity of T cell receptor alpha and beta chain genes expressed by human T cells specific for similar myelin basic protein peptide/major histocompatibility complexes |
| Q34396068 | Does a placebo-effect exist in clinical trials on multiple sclerosis? Review of the literature |
| Q39387198 | Dorsal-column stimulation in the rehabilitation of patients with multiple sclerosis |
| Q37645629 | Early treatment of multiple sclerosis: a Latin American experts meeting |
| Q68957334 | Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations |
| Q58177895 | Electronystagmographic Findings in Multiple Sclerosis |
| Q34369999 | Environmental risk factors in multiple sclerosis aetiology |
| Q40894258 | Epidemiology of multiple sclerosis: a critical overview. |
| Q45744401 | Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis |
| Q48223058 | Evaluation by MRI of paraparesis and tetraparesis of undiagnosed aetiology |
| Q70234167 | Evaluation of Leukocyte Surface Antigens in Patients with Multiple Sclerosis |
| Q54534846 | Evoked potentials are of little use in the diagnosis or monitoring of MS: yes. |
| Q39790686 | Exacerbation history is associated with medication and appointment adherence in MS |
| Q24187235 | Exercise therapy for fatigue in multiple sclerosis |
| Q24202399 | Exercise therapy for fatigue in multiple sclerosis |
| Q24246736 | Exercise therapy for multiple sclerosis |
| Q24250331 | Exercise therapy for multiple sclerosis |
| Q50928170 | Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients |
| Q38648565 | External memory aids for memory problems in people with multiple sclerosis: A systematic review. |
| Q48516971 | Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study |
| Q49161576 | Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence |
| Q44731962 | Fatigue at time of CIS is an independent predictor of a subsequent diagnosis of multiple sclerosis |
| Q40472748 | Fluctuation of Plasma Cortisol Levels in Multiple Sclerosis |
| Q24198247 | Fluoxetine for multiple sclerosis |
| Q77202428 | Functional activity of immune cells in female MS-patients |
| Q69363571 | Further studies on multiple sclerosis in iceland |
| Q64081729 | Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
| Q50616728 | Guidelines for differential diagnosis of suspected multiple sclerosis |
| Q45242162 | HL-A frequencies in patients with multiple sclerosis. |
| Q72718133 | HLA antigens-linked genetic control in multiple sclerosis patients resistant and susceptible to infection |
| Q44239374 | HLA-DR and -DQ allelic sequences in multiple sclerosis patients are identical to those found in the general population |
| Q58290167 | Hearing Status of 30 MS Patients |
| Q68657907 | Heterogeneity in multiple sclerosis: comparison of clinical manifestations in relatives |
| Q33352953 | High performance liquid chromatography as a tool in the definition of abnormalities in monoamine and tryptophan metabolites in cerebrospinal fluid from patients with neurological disorders |
| Q48844459 | High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques |
| Q40160966 | Higher-resolution MR elastography reveals early mechanical signatures of neuroinflammation in patients with clinically isolated syndrome |
| Q35292943 | How different MR imaging criteria relate to the diagnosis of multiple sclerosis and its outcome |
| Q38261156 | Hughes syndrome and multiple sclerosis. |
| Q24247373 | Hyperbaric oxygen therapy for multiple sclerosis |
| Q38632074 | Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. |
| Q38064912 | Imaging and diagnostic criteria for Multiple Sclerosis: Are we there yet? |
| Q51672227 | Impact and characteristics of quality of life in Japanese patients with multiple sclerosis |
| Q49118087 | In vitro stimulation of multiple sclerosis (MS) T and B lymphocytes by autologous monokines generated in the presence of MS-specific brain antigens |
| Q39224378 | Incidence and pattern of demyelinating disease in India |
| Q36096061 | Incidence and prevalence of multiple sclerosis in Newfoundland and Labrador. |
| Q48654997 | Incidental cerebral venous thrombosis in a patient with multiple sclerosis |
| Q50798628 | Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients |
| Q50778662 | Influence of anxiety and reported stressful life events on relapses in multiple sclerosis: a prospective study. |
| Q24195040 | Information provision for people with multiple sclerosis |
| Q24235042 | Information provision for persons with multiple sclerosis |
| Q33590146 | Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study |
| Q34424659 | Interferon in relapsing-remitting multiple sclerosis |
| Q72706155 | Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients |
| Q40093434 | Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients |
| Q39578604 | Intrathecal IgG synthesis in multiple sclerosis and other neurological diseases: A comparative evaluation by IgG-index and isoelectric focusing |
| Q35635127 | Intrathecal effects of daclizumab treatment of multiple sclerosis |
| Q71085343 | Intrathecal synthesis of antibodies to diphtheria and tetanus toxoids in multiple sclerosis patients |
| Q48384229 | Intrathecal synthesis of autoantibodies to myelin basic protein in multiple sclerosis. |
| Q34769676 | Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis |
| Q57267921 | Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis 1 / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking |
| Q38083989 | LSN MS guidelines for the management of multiple sclerosis |
| Q41260520 | Latitude has more significant impact on prevalence of multiple sclerosis than ultraviolet level or sunshine duration in Japanese population |
| Q72733408 | Leukocyte surface antigens in patients with multiple sclerosis |
| Q40169444 | Linoleate and fatty acid compositions in the serum lipids of Japanese patients with multiple sclerosis |
| Q40844658 | Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis |
| Q36071620 | Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study |
| Q51107810 | Long-term survival of patients with multiple sclerosis in West France |
| Q73722382 | Longitudinal study of myelin basic protein-specific T-cell receptors during the course of multiple sclerosis |
| Q47210452 | Lower 25-Hydroxyvitamin D Is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis |
| Q43817952 | Lymphocyte populations and cellular immune reactions in vitro in patients with multiple sclerosis |
| Q39480898 | Lymphocytotoxic antibodies in family members of patients with multiple sclerosis |
| Q40645073 | Lymphocytotoxic antibodies in multiple sclerosis |
| Q39657977 | Lysosomal hydrolases in CSF of patients with multiple sclerosis |
| Q33856610 | Magnetic Resonance Imaging in Multiple Sclerosis: The Role of Conventional Imaging |
| Q69926327 | Magnetic resonance imaging and early diagnosis of multiple sclerosis |
| Q39458420 | Malignant diseases among patients with multiple sclerosis |
| Q50884291 | Mast cells and multiple sclerosis: a light and electron microscopic study of mast cells in multiple sclerosis emphasizing staining procedures |
| Q41938552 | Measles antibodies and histocompatibility types in multiple sclerosis |
| Q70540009 | Measles antibodies detected with various techniques in sera of patients with multiple sclerosis |
| Q45884311 | Measles virus antibodies in serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders, with special reference to measles antibody synthesis within the central nervous system |
| Q52056662 | Memory impairment in multiple sclerosis |
| Q38154241 | Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention |
| Q24245311 | Multidisciplinary rehabilitation for adults with multiple sclerosis |
| Q40158276 | Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up |
| Q39171335 | Multiple Sclerosis and HTLV-I associated myelopathy/tropical spastic paraparesis are two distinct clinical entities |
| Q52052390 | Multiple Sclerosis in Black Children |
| Q40168063 | Multiple Sclerosis: Local Synthesis of Electrophoretically Restricted Measles, Rubella, Mumps and Herpes Simplex Virus Antibodies in the Central Nervous System |
| Q70664931 | Multiple ring enhancement in a case of acute reversible demyelinating disease in childhood suggestive of acute multiple sclerosis |
| Q93541085 | Multiple sclerosis |
| Q94368271 | Multiple sclerosis |
| Q58586681 | Multiple sclerosis |
| Q70888086 | Multiple sclerosis |
| Q72666851 | Multiple sclerosis - lymphocyte transformation with multiple sclerosis and normal brain myelin basic protein and subcellular fractions |
| Q39087979 | Multiple sclerosis amongst Chinese in Taiwan |
| Q39520382 | Multiple sclerosis and canine distemper in Iceland |
| Q47986078 | Multiple sclerosis attacks are associated with picornavirus infections |
| Q43961828 | Multiple sclerosis in childhood: Report of 15 cases |
| Q33932342 | Multiple sclerosis in the Faroe Islands: an epitome |
| Q28303532 | Multiple sclerosis in the faroe islands: I. Clinical and epidemiological features |
| Q48867170 | Multiple sclerosis typical clinical and MRI findings in a patient with HIV infection. |
| Q50564660 | Multiple sclerosis with early childhood onset. A case report |
| Q33876879 | Multiple sclerosis, dental caries and fillings: a case-control study. |
| Q30808302 | Multiple sclerosis. |
| Q34224183 | Multiple sclerosis: current pathophysiological concepts |
| Q50607498 | Multiple sclerosis: relationship between seasonal variations of relapse and age of onset |
| Q72716630 | Multiple sclerosis: the present position |
| Q72653296 | Myelin basic protein antibodies in the serum and CSF of multiple sclerosis and subacute sclerosing panencephalitis patients |
| Q46028265 | NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. |
| Q72213637 | Neuroimaging in multiple sclerosis |
| Q39801476 | Neuropsychology of multiple sclerosis: a critical review |
| Q34636829 | Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis |
| Q41025556 | Neutralizing antibodies to canine distemper and measles virus in multiple sclerosis |
| Q34538571 | Non-parametric analysis of seasonality in birth and multiple sclerosis risk in second generation of migrants in Kuwait |
| Q37821146 | Oligoclonal bands predict multiple sclerosis after optic neuritis: a literature survey |
| Q30654054 | Optic neuritis and multiple sclerosis |
| Q41029401 | Optic neuritis and multiple sclerosis: the T cell repertoires to myelin proteins and MBP peptides change with time |
| Q35588410 | Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America |
| Q42033600 | Overview of azathioprine treatment in multiple sclerosis |
| Q39566082 | Partial purification of MS specific brain antigens |
| Q41453026 | Past infectious events and disease evolution in multiple sclerosis |
| Q47096340 | Pattern Recognition of the Multiple Sclerosis Syndrome |
| Q51001497 | Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distress |
| Q48223363 | Pineal calcification and its relationship to the fatigue of multiple sclerosis |
| Q24236418 | Plasma exchange for multiple sclerosis |
| Q45759916 | Possible association between multiple sclerosis and the human T cell leukemia virus (HTLV)-related endogenous element, HRES-I |
| Q30433837 | Possible clinical outcome measures for clinical trials in patients with multiple sclerosis |
| Q44471923 | Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. |
| Q37606292 | Predicting responders to therapies for multiple sclerosis |
| Q50911464 | Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study |
| Q59490112 | Predominant and stable T cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis |
| Q73901962 | Pregnancy and multiple sclerosis |
| Q84991392 | Prevention of multiple sclerosis: a realistic goal? |
| Q35818146 | Primary progressive multiple sclerosis: cerebrospinal fluid considerations |
| Q34707921 | Primary progressive multiple sclerosis: increasing clarity but many unanswered questions |
| Q77323961 | Problems with diagnostic criteria for multiple sclerosis |
| Q36419573 | Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision |
| Q48626875 | Prospective study on the relationship between infections and multiple sclerosis exacerbations |
| Q36818909 | Providing a neuropsychology service for people with multiple sclerosis in an interdisciplinary rehabilitation unit |
| Q37280335 | Psychological factors affecting neurological conditions. Depression and stroke, multiple sclerosis, Parkinson's disease, and epilepsy |
| Q24244909 | Psychological interventions for multiple sclerosis |
| Q24247870 | Psychological interventions for multiple sclerosis |
| Q57912405 | Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis |
| Q39896698 | Recent advances in multiple sclerosis. |
| Q22252943 | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis |
| Q34233870 | Relapsing and remitting human immunodeficiency virus—associated leukoencephalomyelopathy |
| Q45882676 | Relationship between measles virus-specific antibody activities and oligoclonal IgG in the central nervous system of patients with subacute sclerosing panencephalitis and multiple sclerosis |
| Q34569849 | Relationship between stress and relapse in multiple sclerosis: Part I. Important features |
| Q34658763 | Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity |
| Q58452069 | Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria |
| Q37972189 | Review of methodological issues of clinical trials in multiple sclerosis. |
| Q35087429 | Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review |
| Q52926831 | Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis |
| Q38831720 | Secondary Progressive Multiple Sclerosis: Definition and Measurement. |
| Q34503137 | Secondary progressive multiple sclerosis: current knowledge and future challenges |
| Q48732448 | Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history |
| Q48280176 | Serial recordings of multimodality evoked potentials in multiple sclerosis: a four year follow-up study |
| Q48869655 | Serum IgG to brain microvascular endothelial cells in multiple sclerosis |
| Q48922719 | Sex as a determinant of relapse incidence and progressive course of multiple sclerosis |
| Q43882199 | Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg). |
| Q44568368 | Short vestibulo-ocular reflex time constants associated with oculomotor pathology in multiple sclerosis |
| Q39813893 | Social remedial measures for multiple sclerosis patients in Denmark |
| Q69462684 | Somatosensory Evoked Responses in Patients with Multiple Sclerosis |
| Q45331762 | Some contributions of the Department of Veterans Affairs to the epidemiology of multiple sclerosis |
| Q70969823 | Spinal Cord Swelling in Multiple Sclerosis |
| Q50590100 | Stapedius reflex and brainstem auditory evoked responses in multiple sclerosis patients |
| Q37540661 | Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress |
| Q53165195 | Studies on the clustering of multiple sclerosis in Finland I: Comparison between the domiciles and places of birth in selected subpopulations |
| Q66952334 | Studies on the clustering of multiple sclerosis in Finland II: microepidemiology in one high-risk county with special reference to familial cases |
| Q72838703 | Suppressor T Cells in MS: Do Changes in Numbers Vary with Clinical Activity? |
| Q72799089 | Suppressor T-lymphocytes in multiple sclerosis: Analysis of patients with acute relapsing and chronic progressive disease |
| Q53078951 | Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis |
| Q48329817 | T Cells Recognizing Multiple Peptides of Myelin Basic Protein are Found in Blood and Enriched in Cerebrospinal Fluid in Optic Neuritis and Multiple Sclerosis |
| Q72589337 | T cell receptor gamma delta repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen-reactive gamma delta clones |
| Q44541384 | Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years |
| Q43575541 | Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome |
| Q36565406 | The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis |
| Q33958206 | The Radiologically Isolated Syndrome: Look (Again) Before You Treat |
| Q45839843 | The Usefulness of Gadolinium-Enhanced Images on a Follow-up Magnetic Resonance Image in Suspected Multiple Sclerosis |
| Q51130038 | The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis |
| Q33919855 | The course of early-onset multiple sclerosis in Iraqi children |
| Q71177925 | The diagnosis of multiple sclerosis |
| Q35057227 | The diagnosis of primary progressive multiple sclerosis |
| Q40896928 | The effect of intrathecal MBP synthetic peptides containing epitope P85 VVHFFKNIVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis |
| Q50540092 | The epidemiology of optic neuritis in Finland |
| Q41897509 | The influence of pregnancy on relapses in multiple sclerosis: a cohort study |
| Q74243556 | The myelin basic protein gene in multiple sclerosis: identification of discrete alleles of a 1.3 kb tetranucleotide repeat sequence |
| Q68194203 | The natural history of multiple sclerosis |
| Q57912352 | The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease |
| Q48101206 | The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation |
| Q36501521 | The relation between menarche and the age of first symptoms in a multiple sclerosis cohort |
| Q30800532 | The role of MRI in the diagnosis of MS. |
| Q48437364 | The role of spinal cord imaging in the diagnosis of multiple sclerosis |
| Q68643110 | The treatment of multiple sclerosis |
| Q38092972 | The utility of cerebrospinal fluid analysis in patients with multiple sclerosis |
| Q36215377 | Therapeutic apheresis in neurology critical care |
| Q72742180 | Therapeutic trials in multiple sclerosis |
| Q84476536 | There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - No |
| Q33500910 | Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode |
| Q67244108 | Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone |
| Q53338098 | Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS. |
| Q48614431 | Two unusual neuropathologically proven cases of multiple sclerosis from bombay |
| Q38125058 | Update on Therapeutic Options for Multiple Sclerosis |
| Q37052797 | Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis |
| Q34577652 | Usability and potential of geostatistics for spatial discrimination of multiple sclerosis lesion patterns |
| Q24201719 | Vaccines for preventing influenza in multiple sclerosis patients |
| Q36831490 | Validation of the NARCOMS registry: diagnosis |
| Q46163647 | Vascular endothelial growth factor-A mRNA gene expression in clinical phases of multiple sclerosis |
| Q45798883 | Virus antibodies in the cerebrospinal fluid of multiple sclerosis patients detected with ELISA tests |
| Q39930644 | Virus antibody levels in serum specimens from patients with optic neuritis and from matched controls; |
| Q39930649 | Virus antibody levels in the cerebrospinal fluid from patients with optic neuritis |
| Q36045080 | Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up |
| Q24235702 | Vitamin D for the management of multiple sclerosis |
| Q24239892 | Vitamin D for the management of multiple sclerosis |
| Q34499681 | What went wrong in the natalizumab trials? |
| Q38634654 | William Austin Sibley, MD (1925-2015). |
| Q79793902 | [Can multiple sclerosis be diagnosed on a first demyelinating event?] |
| Q46016507 | [Multiple sclerosis and physical activity: an historical perspective]. |
Search more.